Core Viewpoint - The company demonstrates resilience and brand strength with revenue and profit growth in H1 2025 despite external challenges, and is expected to accelerate growth in H2 due to upcoming promotional activities [1] Group 1: Financial Performance - In H1 2025, the company's revenue and profit increased, with revenue growth rates of 22.7% for 可复美 and 26.9% for 可丽金 [1] - The GMV for 可复美 and 可丽金 in July reached 1.72 billion and 0.19 billion respectively, showing year-on-year growth of 48% and 77% [1] - The company maintains its profit forecast with expected net profits of 26.00 billion, 32.03 billion, and 38.12 billion for 2025-2027 [3] Group 2: Product and Innovation - The company has obtained exclusive patents for new products, including a restructured IV type collagen and ginsenoside-rich fermented ginseng products, enhancing its R&D capabilities [2] - The brand is actively promoting its products through various channels, including a successful live-streaming event on September 8 that generated over 16 million in GMV [1][2] Group 3: Market Expansion - The company is expanding its market presence, having entered the Malaysian market and established a joint venture to target Southeast Asia [2] - The brand has also made inroads into the South Korean and French markets, with product launches in key retail locations [2] Group 4: Valuation and Target Price - The company maintains a target price of 85.0 HKD for 2025, reflecting a PE ratio of 31 times, adjusted from a previous target of 82.50 HKD [3] - The valuation considers the company's successful brand promotion and overseas channel development [3]
巨子生物(2367.HK)：品牌定力与业绩韧性彰显 期待25H2增长提速